A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Tre

Grants and Contracts Details

StatusActive
Effective start/end date12/20/24 → 12/20/26

Funding

  • ICON Clinical Research: $12,973.00